Angela DeMichele, MD, MSCE

Denkert C, Rachakonda S, Pehl A, Marmé F, Martin M, Karn T, Untch M, Bonnefoi H, Kim SB, Hirmas N, Bear H, Witkiewicz AK, Im SA, DeMichele A, Veer LV, McCarthy N, Stiewe T, Jank P, Gelmon KA, García-Sáenz JA, Westhoff C, Kelly CM, Reimer T, Olivé MM, Knudsen ES, van Mackelenbergh M, Rojo F, Frickel N, Fasching PA, Teply-Szymanski J, Toi M, Rugo HS, Gnant M, Makris A, Felder B, Nekljudova V, Loibl S. Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial Cohort. , Mod Pathol.: 2026

Sun X, Ocampo AA, Hanna A, Taylor BC, Marshall JL, Steele JA, Axelrod ML, Wescott EC, Opalenik SR, DeMichele A, Esserman LJ, Liu MC, Nanda R, Wolf DM, Brown Swigart L, Hirst GL, van 't Veer LJ, Xu Y, Balko JM. Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer , Sci Transl Med: 2026

Hunter NB, Parsons HA, Cope L, Canzoniero JV, Navarro FCP, El-Refai S, Anampa JD, Sparano JA, Rimawi M, Storniolo AM, Mainor C, Nanda R, DeMichele A, Gupta GP, Stringer-Reasor EJ, Lynce F, Cobain EF, Puhalla S, Jankowitz R, Rexer B, Mayer I, Hwang ES, Blackwell K, El Ayass W, Lee Y, Tweed C, Wilkinson M, Pennisi A, Sun B, Wright P, Gralow JR, Chen R, Boyle SM, Stearns V, Wolff AC, Park BH. The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease , J Clin Oncol.: 2026

Metzger O, Mandrekar S, Goel S, Gligorov J, Lim E, Ciruelos E, Loibl S, Dockter T, Gonzàlez Farré X, Francis PA, Lynce F, Lanzillotti J, DuFrane C, Wall A, Strand C, Krop I, Vaz-Luis I, Tripathy D, Loi S, Prat A, Goetz M, Escrivá-de-Romaní S, Porter D, Spoenlein J, Stover DG, Sardesai S, Heudel P, Koehler M, Huang Bartlett C, Holynskyj A, Gopalakrishna P, Gauthier E, Delaloge S, Miller K, Winer EP, Gianni L, Partridge AH, DeMichele A, Carey LA. Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer , N Engl J Med: 2026

Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, Tin A, Renner D, Kalashnikova E, Brown-Swigart L, Hirst GL, Yau C, Li W, Isaacs C, Shatsky RA, Clark AS, Zimmer A, Delson AL, Rodriguez A, Liu MC, Pohlmann PR, Esserman LJ, Rugo HS, DeMichele A, van 't Veer L. Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. , Nat Commun: 2025

Chislock EM, Pan TC, Pant D, Chen Y, Woodfield G, Graves J, Lawrence-Paul MR, Belka GK, Wang J, Bayne L, Blanchard T, Smith M, Ji X, Shih NNC, Soucier-Ernst D, Goodman N, Nivar I, Goodspeed B, DeLuca S, Ndicu J, Clark C, Langer M, William Stavropoulos S, DeMuth W, Morschauser A, Murphy W, Nayak A, Feldman M, Clark A, Yu L, Judge K, Bornheimer S, Pletcher CH Jr, Moore JS, DeMichele A, Chodosh LA. DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer , NPJ Breast Cancer : 2025

Gerratana L, Reduzzi C, Ren Y, Jeselsohn R, Mahtani RL, Ma CX, DeMichele A, Meisel JL, Miller K, Abdou Y, Riley EC, Qamar R, Sharma P, Reid SA, Ko N, Liu Y, Gauthier E, Burstein HJ, DeMeo M, Tolaney SM, Regan MM, Cristofanilli M, Mayer EL. Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study. , Clin Cancer Res: 2025

Thomas A, Rhoads A, Mayer EL, O'Reilly S, Harbeck N, Curigliano G, Zhou Y, Adam V, Chan N, Conway KM, Ignatiadis M, Kalinsky K, DeMichele A, Romitti PA. Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021. , NPJ Breast Cancer: 2025

Hennessy, M. A., Gatsonis, C., Jacene, H., Connolly, R. M., Burnette, B. L., Stringer-Reasor, E. M., Romanoff, J., Taurone, A., O'Sullivan, C. C., Le-Petross, H. T., Stearns, V., Fowler, A. M., Tang, S., Sepulveda, K. A., DeMichele, A. M., Mankoff, D. A., Wolff, A. C. EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial) , Future Oncology : 2025

DeMichele, A., Clark, A. S., Shea, E., Bayne, E. J., Sterner, C. J., Rohn, K., Dwyer, S., Pan, T., Nivar, I., Chen, Y., Wileyto, P., Berry, L. R., Deluca, S., Savage, J., Makhlin, I., Pant, D. K., Martin, H., Egunsola, A., Mears, N., Goodspeed, B. L., Chislock, E. M., Graves, J., Wang, J., Shih, N., Belka, G. K., Berry, D., Nayak, A., Feldman, M., & Chodosh, L. A. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial , Nature Medicine: 2025